Send to

Choose Destination
Am J Transplant. 2015 Oct;15(10):2739-49. doi: 10.1111/ajt.13329. Epub 2015 May 26.

Pilot Study Evaluating Regulatory T Cell-Promoting Immunosuppression and Nonimmunogenic Donor Antigen Delivery in a Nonhuman Primate Islet Allotransplantation Model.

Author information

Center for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.


The full potential of islet transplantation will only be realized through the development of tolerogenic regimens that obviate the need for maintenance immunosuppression. Here, we report an immunotherapy regimen that combines 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (ECDI)-treated donor lymphoid cell infusion (ECDI-DLI) with thymoglobulin, anti-interleukin-6 receptor antibody and rapamycin to achieve prolonged allogeneic islet graft survival in a nonhuman primate (NHP) model. Prolonged graft survival is associated with Treg expansion, donor-specific T cell hyporesponsiveness and a transient absence of donor-specific alloantibody production during the period of graft survival. This regimen shows promise for clinical translation.


Donor-specific hyporesponsiveness; donor-specific transfusion/antigen delivery; graft survival; tolerance; tolerance: depletion

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center